SOURCE: RoboticOncology.com

RoboticOncology.com

March 05, 2009 10:35 ET

World-Renowned Prostate Surgeon David B. Samadi, M.D. Clarifies Prostate Screening and Treatment Options for Primary Care Physicians in Geriatrics Medical Journal

NEW YORK, NY--(Marketwire - March 5, 2009) - Dr. David B. Samadi, who is trained in open, laparoscopic, and robotic surgery and is one of the most experienced robotic prostatectomy surgeons in the world, has published an overview of current prostate cancer screening and treatment options for the benefit of the primary care physician readership of Geriatrics, a peer-reviewed monthly medical journal, and the 50+ year old patients they serve. The article, "Organ-confined prostate cancer and the emergence of robotic prostatectomy: what primary care physicians and geriatricians need to know," graces the cover of Geriatrics' February 2009 issue (Volume 64, Number 2). It can be viewed in its entirety at no charge at the Geriatrics website, http://geriatrics.modernmedicine.com.

Prostate Cancer Screening Options

The current methods for diagnosing prostate cancer involve using serum prostate-specific antigen (PSA) and digital rectal examination (DRE) tests. Although these methods have saved countless lives through early diagnosis since their adoption in the late 1980s, the interpretation of PSA results remains a challenge due to the natural fluctuations of PSA levels even in healthy men. In the article, Dr. Samadi predicts, "It now appears likely that PSA velocity (calculated over the course of at least 18 months) is more predictive of prostate cancer than the absolute PSA value."

Organ-Confined Prostate Cancer Treatment Options

Current treatment options for organ-confined prostate cancer (metastatic disease is beyond the scope of the article) include surgery, radiation therapy, and active surveillance. Dr. Samadi concurs with the consensus view that active surveillance is the preferred treatment method for much older patients with low-grade, low-stage disease. For others, however, he says "Prostate surgery is considered the 'gold standard.'" Dr. Samadi then provides a detailed discussion of the reasoning behind experts' (and patients') preference for radical prostatectomy over radiotherapy and the additional advantages of robotic surgery in achieving, among other benefits, what he terms "the three goals of successful radical prostatectomy... cancer control (margins), urinary continence, and potency."

About Geriatrics Medical Journal

Over 70,000 physicians per month turn to Geriatrics for practical, peer-reviewed, evidence-based clinical guidance on providing quality care for patients aged 50 and older in the community and the long-term care setting. This monthly medical journal targets the practical day-to-day needs of primary care physicians, geriatricians, and long-term care professionals whose patients include midlife and older adults. Articles published in Geriatrics are listed in Index Medicus and Current Contents.

About David B. Samadi, M.D.

David B. Samadi, M.D. is Chief, Division of Robotics and Minimally Invasive Surgery at Mount Sinai School of Medicine in New York City. He is a board certified Urologic Oncologist, specializing in the diagnosis and treatment of kidney, bladder, and prostate cancer, using minimally invasive procedures like da Vinci surgery. If you would like more information about Dr. Samadi's state-of-the-art treatment options, including the robotic prostatectomy, please don't hesitate to call him at 1-888-Robot10 (1-888-762-6810), or visit him on the web at www.roboticoncology.com.